CAR T-Cell Therapy: Genetically Programming the Immune System to Attack Malignant Cells
February 25th 2020Current FDA-approved CAR-T cell therapies express CARs recognizing CD19, which is expressed on the surface of almost all B cells, making these therapies specific for B-cell malignancies.
Read More
2 Commerce Drive
Cranbury, NJ 08512